When Boehringer Ingelheim GMBH in-licensed the prostatic hyperplasia treatment tamsulosin (Flomax) from Astellas Pharma Inc. in 1994 [See Deal], the private German company had zero experience in urology. Boehringer, in fact, at first underestimated Flomax's potential, and initial sales reflected this limited faith: the drug that has become the company's strongest seller, with €613 million ($629 million) in 2001 sales, started off slowly.
Boehringer's December 2002 co-promotion deal for duloxetine with Eli Lilly & Co.[See Deal], while expanding its presence in...




